Race Oncology Limited

ASX:RAC.AX

1.7 (AUD) • At close September 16, 2024
Bedrijfsnaam Race Oncology Limited
Symbool RAC.AX
Munteenheid AUD
Prijs 1.7
Beurswaarde 289,720,800
Dividendpercentage 0%
52-weken bereik 0.64 - 2.09
Industrie Biotechnology
Sector Healthcare
CEO Dr. Peter M. Smith Ph.D.
Website https://www.raceoncology.com

An error occurred while fetching data.

Over Race Oncology Limited

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which

Vergelijkbare Aandelen

Aroa Biosurgery Limited logo

Aroa Biosurgery Limited

ARX.AX

0.485 AUD

Paradigm Biopharmaceuticals Limited logo

Paradigm Biopharmaceuticals Limited

PAR.AX

0.25 AUD

Pacific Smiles Group Limited logo

Pacific Smiles Group Limited

PSQ.AX

1.755 AUD

Rhythm Biosciences Limited logo

Rhythm Biosciences Limited

RHY.AX

0.065 AUD

Cogstate Limited logo

Cogstate Limited

CGS.AX

0.95 AUD

Starpharma Holdings Limited logo

Starpharma Holdings Limited

SPL.AX

0.098 AUD

Anteris Technologies Ltd logo

Anteris Technologies Ltd

AVR.AX

12.7 AUD

PYC Therapeutics Limited logo

PYC Therapeutics Limited

PYC.AX

0.135 AUD

Immutep Limited logo

Immutep Limited

IMM.AX

0.355 AUD

AnteoTech Limited logo

AnteoTech Limited

ADO.AX

0.023 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)